Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US10864203B2 · kind B2 · utility
8Cited by
73References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 14, 2017 |
| Grant date | Dec 15, 2020 |
| Priority date | — |
| Expiry date | Jun 14, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.